Kalpataru Projects secures ₹989 crore orders in overseas power T&D segment

Published : Jul 01, 2025, 09:00 AM IST
https://stocktwits.com/news-articles/markets/equity/kalpataru-projects-share-price-secures-rs-989-crore-orders-in-overseas-power-td-segment-19629388/chmZA9tRRfU

Synopsis

The fresh orders pertain to the power transmission & distribution (T&D) segment in overseas markets. Shares of Kalpataru Projects International Limited ended at ₹1,215.60 down by ₹9.80, or 0.80%, on the BSE.

Kalpataru Projects International Limited (KPIL) on Monday (June 30) said the company, along with its international subsidiaries, has secured new orders and notification of awards worth approximately ₹989 crore.

The fresh orders pertain to the power transmission & distribution (T&D) segment in overseas markets.

Kalpataru Projects International posted a strong 37.2% year-on-year rise in consolidated net profit for Q4FY25 at ₹225.4 crore, up from ₹164.3 crore a year ago, supported by healthy execution across segments.

Also Read: Kalpataru Projects eyes margin expansion in FY26 as order inflow gains momentum

Revenue grew 18.3% to ₹7,066.7 crore from ₹5,971.2 crore in Q4FY24. EBITDA rose 18.9% to ₹537.8 crore from ₹452 crore in the same period. Margins remained stable, with the EBITDA margin at 7.6% versus 7.5% a year earlier.

For the full year, revenue rose 14% to ₹22,316 crore from ₹19,572 crore in FY24. EBITDA was up 13% to ₹1,834 crore, while PBT increased 17% to ₹823 crore. Net profit for the year stood at ₹567 crore.

Order inflows for FY25 totalled ₹25,475 crore, taking the order book to ₹64,495 crore as of March 31, 2025. Net debt stood at ₹1,953 crore.

Shares of Kalpataru Projects International Limited ended at ₹1,215.60 down by ₹9.80, or 0.80%, on the BSE.

Also Read: Kalpataru Projects shares surge 5% after buildings and factories business wins ₹3,789 crore order

PREV

Recommended Stories

Can CoreWeave’s Q2 Print Prolong Stock Rally? Analysts, Retail Traders Hopeful Of AI Growth Potential
Can CoreWeave’s Q2 Print Prolong Stock Rally? Analysts, Retail Traders Hopeful Of AI Growth Potential
Retail Turns Bearish On Bayer After $1.3B Kumquat Cancer Drug Deal